SCHEDULE: FMR LLC Reports 10.3% Stake in Inovio Pharmaceuticals

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 10.3% in Inovio Pharmaceuticals as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, indicating their beneficial ownership of Inovio Pharmaceuticals' common stock.
• As of June 30, 2026, the total beneficial ownership reported is 8,454,797 shares, representing 10.3% of the class of securities.
• FMR LLC holds sole voting power and sole dispositive power for 8,454,780 shares, while Abigail P. Johnson's filing reflects the same aggregate amount of beneficial ownership.
• Fidelity Small Cap Growth Fund is noted as having an interest of 5,632,660 shares, or 6.8% of the total outstanding common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes rather than company performance or strategic shifts.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson indicates confidence in Inovio Pharmaceuticals.
• The filing clearly delineates the beneficial ownership structure, providing transparency to investors.

Negatives

• The filing does not provide any financial performance data or operational updates for Inovio Pharmaceuticals.
• The information is historical, reflecting ownership as of June 30, 2026, and may not represent current holdings.

Risks

• The concentration of ownership by a single reporting entity could potentially influence corporate governance decisions.
• Changes in beneficial ownership by large holders can sometimes precede significant strategic shifts or market movements.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Inovio Pharmaceuticals' future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. This filing indicates a substantial investment by FMR LLC in the biotechnology sector, specifically in Inovio Pharmaceuticals.

Stakeholder Impact

• Shareholders: Increased institutional ownership may signal investor confidence, potentially impacting share price and corporate strategy.
• Management: The significant stake held by FMR LLC and Abigail P. Johnson could influence board composition and strategic decisions.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold and potentially manage their beneficial ownership in Inovio Pharmaceuticals.

Key Dates

Keywords

Inovio Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Fidelity Small Cap Growth Fund